Medical Packaging : DuPont P&IP to market authentication technologies

DuPont Packaging & Industrial Polymers (P&IP) and its Security & Solutions Business will market two technologies arming brand owners with some necessary tools in the ongoing fight against counterfeiting and tampering.

Developed by identif GmbH of Erlangen, Germany, Bio-Molecular Fingerprint (covert) and Color Spectra Film (overt) include human and machine detectable "signatures" that can be integrated into forgery-proof packaging or labelling for many essential products.

Utilising a combination of machine-readable and user-observable product authentication technologies, Bio-Molecular Fingerprint and Color Spectra Film can increase the product safety, performance and brand exclusivity of pharmaceuticals, luxury goods, arts and media products, branded apparel and automotive parts, a release stated.

Bristol-Myers Squibb uses identif GmbH authentication technology in the packaging of its anti-cancer and HIV drugs to avoid tampering or misrepresentation. DuPont P&IP's marketing of identif Technologies is a direct result of its purchase of an equity stake in the German company and a continuation of its packaging systems into the security technologies market as an integrator & solutions provider.

(Ref : "Chronicle Pharmabiz" dated March 31, 2005)

Health Ministry plans 50 testing labs in 3 years

The Ministry of Health & Family Welfare has launched a major initiative to set up 50 state-of-the-art drug testing laboratories across the country within three years. While 20 of them are to be entirely new facilities, rest would come up through renovation and modernisation of existing laboratories.

"All the 50 laboratories that are coming up in the country are to be NABL accredited. With the new laboratory facilities, the drug regulatory authority will be able to test thrice the number of drug samples in a year within a much lesser time", Teaotia said. With the upgraded capacity and the new laboratories, it is expected that about one lakh samples of drug would be tested for safety and quality per year.

(Ref : "Chronicle Pharmabiz" dated March 31, 2005)